The Food and Drug Administration has approved GLP-1 medications for treating type 2 diabetes and obesity
By binding to GLP-1 receptors, Ozempic exerts multiple physiological effects: Enhances glucose-dependent insulin secretion from pancreatic beta cells, improving glycaemic control Suppresses glucagon release , reducing hepatic glucose production Slows gastric emptying , which moderates post-prandial glucose excursions Acts on appetite centres in the brain , particularly the hypothalamus, reducing hunger and promoting satiety These combined actions result in improved blood glucose regulation and, notably, weight loss
^ Luhovyy B L, Kathirvel P
Etiology of subjective taste loss
Plants 14 (12), 88106
Geopolitics2 months ago Mapped: The Worlds Key Maritime Trade Chokepoints Explore the worlds busiest shipping routes and maritime chokepoints, and see how disruptions can create risks for global trade and supply chains